Format

Send to

Choose Destination
See comment in PubMed Commons below
Heart Fail Clin. 2014 Jul;10(3):453-70. doi: 10.1016/j.hfc.2014.04.006. Epub 2014 May 22.

Natriuretic peptides in heart failure with preserved ejection fraction.

Author information

1
Cardiac Department, Cardiovascular Research Institute, National University Heart Centre, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block, Level 9, Singapore 119228, Singapore; Department of Medicine, Christchurch Heart Institute, University of Otago, Christchurch, 2 Riccarton Avenue, Christchurch 8140, New Zealand. Electronic address: mdcarthu@nus.edu.sg.
2
Cardiac Intensive Care Unit, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.
3
Department of Medicine, Christchurch Heart Institute, University of Otago, Christchurch, 2 Riccarton Avenue, Christchurch 8140, New Zealand.

Abstract

Timely diagnosis, early introduction of appropriate treatment, accurate risk stratification, and optimal titration of therapy are all key to the management of acute and chronic heart failure (HF). Plasma concentrations of the cardiac natriuretic peptides (NPs) are valuable aids in each of these elements of care. However, most data are derived from cohorts with undifferentiated HF or HF with reduced ejection fraction (HFREF), and the performance and best application of NPs in HF with preserved ejection fraction (HFPEF) is less certain. This review outlines the evidence for use of NPs in the evaluation and management of HFPEF.

KEYWORDS:

B-type natriuretic peptide; Cardiac natriuretic peptides; Diagnosis; Heart failure; N-terminal prohormone B-type natriuretic peptide; Prognosis

PMID:
24975909
DOI:
10.1016/j.hfc.2014.04.006
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center